Market Overview

UPDATE: Goldman Sachs Reiterates Sell Rating, $62 PT on Humana

Share:
Related HUM
Don't Expect Failed Humana Deal To Quash Aetna's Desire For M&A
Benzinga's Top Upgrades, Downgrades For June 28, 2017

In a report published Wednesday, Goldman Sachs Group reiterated its Sell rating and $62.00 price target on Humana (NYSE: HUM).

Goldman Sachs noted, “The focus of the investor day was the transition to provider-integrated care (owned and risk-contracted) that offers lower cost / higher quality outcomes versus traditional fee-for-service. With Medicare Advantage (MA) driving the majority of revenue and earnings, we think integrated care is the right model to better position Humana for tighter MA reimbursement as health reform rolls through and also the right model to strengthen Humana's role in easing the national Medicare cost crisis in the years ahead.”

Humana closed on Tuesday at $68.29.

Latest Ratings for HUM

DateFirmActionFromTo
Jul 2017Bank of AmericaMaintainsBuy
Jun 2017CitigroupInitiates Coverage OnBuy
Jun 2017ArgusUpgradesHoldBuy

View More Analyst Ratings for HUM
View the Latest Analyst Ratings

Posted-In: Goldman Sachs GroupAnalyst Color Reiteration Analyst Ratings

 

Related Articles (HUM)

View Comments and Join the Discussion!